Cover Image

Early assessment of chemotherapy response in advanced non-small cell lung cancer with circulating tumor DNA

Monitoring treatment efficacy early during therapy could enable a change in treatment to improve patient outcomes. We report an early assessment of response to treatment in advanced NSCLC using a plasma-only strategy to measure changes in ctDNA levels after one cycle of chemotherapy. Plasma samples...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaung, Stephanie (Author) , Woestmann, Corinna (Author) , Ju, Christine (Author) , Ma, Xiaoju Max (Author) , Gattam, Sandeep (Author) , Zhou, Yiyong (Author) , Xi, Liu (Author) , Pal, Subrata (Author) , Balasubramanyam, Aarthi (Author) , Tikoo, Nalin (Author) , Heußel, Claus Peter (Author) , Thomas, Michael (Author) , Kriegsmann, Mark (Author) , Meister, Michael (Author) , Schneider, Marc (Author) , Herth, Felix (Author) , Wehnl, Birgit (Author) , Diehn, Maximilian (Author) , Alizadeh, Ash A. (Author) , Palma, John F. (Author) , Muley, Thomas (Author)
Format: Article (Journal)
Language:English
Published: 2022
In: Cancers
Year: 2022, Volume: 14, Issue: 10, Pages: 1-14
ISSN:2072-6694
DOI:10.3390/cancers14102479
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers14102479
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/14/10/2479
Get full text
Author Notes:Stephanie J. Yaung, Corinna Woestmann, Christine Ju, Xiaoju Max Ma, Sandeep Gattam, Yiyong Zhou, Liu Xi, Subrata Pal, Aarthi Balasubramanyam, Nalin Tikoo, Claus Peter Heussel, Michael Thomas, Mark Kriegsmann, Michael Meister, Marc A. Schneider, Felix J. Herth, Birgit Wehnl, Maximilian Diehn, Ash A. Alizadeh, John F. Palma and Thomas Muley
Description
Summary:Monitoring treatment efficacy early during therapy could enable a change in treatment to improve patient outcomes. We report an early assessment of response to treatment in advanced NSCLC using a plasma-only strategy to measure changes in ctDNA levels after one cycle of chemotherapy. Plasma samples were collected from 92 patients with Stage IIIB-IV NSCLC treated with first-line chemo- or chemoradiation therapies in an observational, prospective study. Retrospective ctDNA analysis was performed using next-generation sequencing with a targeted 198-kb panel designed for lung cancer surveillance and monitoring. We assessed whether changes in ctDNA levels after one or two cycles of treatment were associated with clinical outcomes. Subjects with ≤50% decrease in ctDNA level after one cycle of chemotherapy had a lower 6-month progression-free survival rate (33% vs. 58%, HR 2.3, 95% CI 1.2 to 4.2, log-rank p = 0.009) and a lower 12-month overall survival rate (25% vs. 70%, HR 4.3, 95% CI 2.2 to 9.7, log-rank p < 0.001). Subjects with ≤50% decrease in ctDNA level after two cycles of chemotherapy also had shorter survival. Using non-invasive liquid biopsies to measure early changes in ctDNA levels in response to chemotherapy may help identify non-responders before standard-of-care imaging in advanced NSCLC.
Item Description:Published: 18 May 2022
This article belongs to the Special Issue Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers
Gesehen am 08.07.2022
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14102479

Similar Items